Lupin Ltd Q3 FY2024 Concall Summary

Key Takeaways

• Record quarter, margin leap: Sales crossed INR 5,000 crores for the first time, while EBITDA margin jumped to 20.1% from 12.2% a year ago, driven by a richer product mix and operating leverage.
• US business finds a durable floor: The US delivered a second straight \$200 mn+ quarter, with volume-led base business growth and a fast-ramping Tiotropium; management now targets 40%+ market share for the product.
• India is the growth engine, not just a contributor: India grew at 1.6x the IPM rate, led by chronic therapies and a #1 new-launch ranking; the company is doubling down with new divisions and an extra-urban push.
• The margin story has a clear, multi-year path: Near-term EBITDA is guided to 19.5–20.5%, but the stated goal is 22–23% "as early as possible," fueled by a complex generics pivot and a INR 500 crore cost takeout plan that is already underway.
• What to watch next quarter: The outcome of Mirabegron and Slynd patent litigation, the clearance of Tarapur and Mandideep Unit 1 sites, and whether the US business can sustain its \$200 mn+ run-rate without the Q2 channel load-in benefit.

US Business: The Complex Generics Pivot

• Tiotropium is the new anchor: The product is ramping strongly, with scripts growing nicely; management revised its market share target upward to 40%+ and expects to be alone in the market for the next couple of years, protected by challenging manufacturing and Lupin's own patents.
• Respiratory share normalizes, not declines: The respiratory portfolio's share of US revenue dipped from 45% to 40%+ sequentially, but this was driven entirely by Tiotropium channel load-in timing in Q2 and some Albuterol seasonality, not by any product erosion.
• Base business strength offsets price erosion: Oral solids saw low-single-digit price erosion, fully offset by volume growth; drug shortages across the industry have helped normalize pricing pressure as manufacturers exit unprofitable lines.
• The pipeline is shifting toward injectables and ophthalmics: 14 ANDA approvals in the quarter included the first peptide injectable (Ganirelix); multiple ophthalmic and complex injectable launches are expected to sustain the \$200 mn+ run-rate.
• Litigation outcomes are the swing factor for FY25: Single-digit US growth is the base case for next year; if Mirabegron and Slynd patent litigation succeeds, growth could hit double digits, with a potential Mirabegron launch as early as Q1 FY25.

Vinita Gupta: "We feel pretty good about the potential of being alone in the market over the next couple of years. And if you just look at what it took for us to get approval of the product, it was five years at the FDA, and that was because the product is a pretty challenging product."

India Business: Doubling Down on the Home Market

• Growth leadership is structural, not cyclical: India grew at 1.6x the IPM growth rate, with Respiratory, GI, and Gynaecology all outperforming the market; chronic therapies now account for over 60% of India sales.
• New launch engine is the best in the industry: Lupin ranked #1 in new product launches in India per IQVIA, with 21 launches in the last nine months, including some "first in the world" launches in Respiratory.
• Field force expansion is still in investment mode: Reps were added only in the last year, and all divisions are performing as expected; per-capita productivity is expected to keep improving, providing a clear operating leverage tailwind.
• Extra-urban and new divisions are the next leg: An extra-urban division has been launched, and a couple more divisions will be added in the next two quarters; the company is also strategically looking to buy brands and portfolios to build a stronger therapy-area position.

Nilesh Gupta: "I think the idea is to make bigger brands. We're doing that in Respiratory, we're doing that in Cardiovascular and Diabetes as well. But there's also this opportunity to focus on extra-urban. So yeah, we are doubling down on India."

Margin Trajectory: The 22–23% Glide Path

• The quarter's jump was broad-based: Gross margin hit 66% vs 59.8% last year, driven by product mix, lower in-licensed product share, and higher volumes; employee costs rose on annual hikes and field force expansion, but operating leverage more than compensated.
• Adjacencies are a 2.5-point drag today: Digital, diagnostics, and OTC businesses are currently dilutive; per management's own math, excluding these adjacencies would add roughly 2.7 percentage points to reported EBITDA margin, implying a core business already near the target range.
• The cost takeout plan is real but partially camouflaged: The INR 500 crore cost reduction program has "achieved quite a bit," but the savings are being reinvested ahead of the curve; remaining inefficiencies include inventory write-offs, air freighting, and idle time.
• Complex generics make margins stickier: The portfolio mix has evolved to 40–45% inhalation, with injectables adding next year; these categories do not see the price erosion typical of oral solids, and the oral solids segment itself has stabilized over the last 12 months.
• Latin America is the lagging geography: Mexico faces factory issues and Brazil has business challenges; India is growing nicely but is still in investment mode and not yet at a 20%+ margin level, though operating leverage is steadily improving.

Ramesh Swaminathan: "Having said all of that, the fact of the matter is our EBITDA margins are still lower than the competition and we would like to get to the 22.5%, 23% range. But given all of this, the moving parts, we would like to state that it should be between the 19.5% to 20.5%. But clearly, the pathway is to get to the 22%, 23% as early as possible."

Pipeline & Portfolio: What Comes Next

• Near-term catalysts are stacked: Tolvaptan is expected as a material launch early in FY26; Liraglutide (Victoza, Saxenda) is already filed and should reach the market in the FY25–26 timeframe; Pegfilgrastim's CRL response goes in within three months, with approval possible by end-FY25 or just after.
• Inhaler platforms are the next frontier: At least one, possibly two products across the Respimat and Ellipta platforms should be taking exhibit batches and potentially filing within the next 12 months; Dulera's CRL response will be filed based on agency feedback in the next three months or so.
• GLP-1 timeline is long but defined: Semaglutide is targeted for the FY28–29 timeframe; Mounjaro and Ozempic are "out a little bit further," making GLP-1s a material contributor only in the outer years of the margin target window.
• Xarelto is a known non-event for now: Despite receiving tentative approval on an \$8.3–\$8.5 billion market, management explicitly stated it is not a product launch in the next two years.
• Specialty aspirations are alive but patient: The first foray was not successful, but management is studying the space and says it is a "question of time" before getting back; respiratory and neurology are the programmatic capital deployment priorities, with other areas opportunistic.

Capital Position & Operational Discipline

• Balance sheet transformed in nine months: Net debt reduced from INR 2,527 crores to INR 1,043 crores, a reduction of roughly INR 1,500 crores; the company expects to be debt-free by year-end.
• Working capital tightened sharply: Working capital days improved to 96 from 135 as of December 31, 2022, reflecting a disciplined focus on cash conversion alongside profit growth.
• Oral solids are managed for cash, not growth: The strategy is to run the baseline efficiently with strong cost focus on KSMs and related spend, minimizing idle costs; products that do not contribute to the P&L will not be sustained, though there is no single margin cut-off number.
• Acquisitions remain on the table: The company has always been acquisitive and will look at deals when the proposition is compelling, with respiratory and neurology as programmatic areas and India brand/portfolio buys as a strategic focus.

Vinita Gupta: "Our focus on oral solids is the baseline. We want to manage it as efficiently as possible. It's a very, very strong focus on cost improvement there through KSMs and other related spend, making sure that we don't have idle costs."

Guidance & Commitments

Key Metrics